LianBio operates as a biopharmaceutical company, which engages in the development and commercialization of medicines for patients with unmet medical needs. The company is headquartered in Princeton, New Jersey and currently employs 163 full-time employees. The company went IPO on 2021-10-28. The firm is also pursuing the sale of its remaining pipeline assets.
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for LIANY. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: LIANY is a Sell candidate.
LIANY stock price ended at $0.11 on 木曜日, after dropping 21.43%
On the latest trading day May 14, 2026, the stock price of LIANY fell by 21.43%, dropping from $0.11 to $0.11. During the session, the stock saw a volatility of 0.00%, with prices oscillating between a daily low of $0.11 and a high of $0.11. On the latest trading day, the trading volume for LIANY rose by 9.0K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 9.9K shares were traded, with a market value of approximately $11.8M.